Inhibition of angiogenesis by Aβ peptides

Angiogenesis

Volumn 7, Issue 1, 2004, Pages 75-85

  Paris, Daniel ^a   Townsend, Kirk ^a   Quadros, Amita ^a   Humphrey, James ^a   Sun, Jiazhi ^b   Brem, Steven ^b   Wotoczek Obadia, Marguerite ^b   DelleDonne, Anthony ^a   Patel, Nikunj ^a   Obregon, Demian F ^a   Crescentini, Robert ^a   Abdullah, Laila ^a   Coppola, Domenico ^b   Rojiani, Amyn M ^b   Crawford, Fiona ^a   Sebti, Saïd M ^b   Mullan, Michael ^a  

^a ROSKAMP INSTITUTE   (United States)

^b H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

amyloid; A ; adenocarcinoma; angiogenesis; glioblastoma

Indexed keywords

AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; ANGIOGENESIS INHIBITOR; MATRIGEL; N (2 CYCLOHEXYLOXY 4 NITROPHENYL)METHANESULFONAMIDE; PEPTIDE DERIVATIVE; UNCLASSIFIED DRUG; AMYLOID BETA PROTEIN; PEPTIDE FRAGMENT;

ADULT; ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; AORTA; ARTICLE; BETA SHEET; CAPILLARY; CHORIOALLANTOIS; CONTROLLED STUDY; DOSE RESPONSE; ENDOTHELIUM CELL; FEMALE; GLIOBLASTOMA; HUMAN; HUMAN CELL; HUMAN TISSUE; LUNG ADENOCARCINOMA; MIDDLE CEREBRAL ARTERY; MOUSE; NONHUMAN; PRIORITY JOURNAL; RAT; TUMOR GROWTH; TUMOR XENOGRAFT; ANIMAL; CANCER TRANSPLANTATION; CELL CULTURE; CELL PROLIFERATION; CYTOLOGY; DRUG EFFECT; EXPERIMENTAL NEOPLASM; NEOVASCULARIZATION (PATHOLOGY); NUDE MOUSE; TREATMENT OUTCOME; TUMOR CELL LINE; VASCULAR ENDOTHELIUM; XENOGRAFT;

ANIMALIA; MUS MUSCULUS;

AMYLOID BETA-PROTEIN; ANGIOGENESIS INHIBITORS; ANIMALS; CELL LINE, TUMOR; CELL PROLIFERATION; CELLS, CULTURED; ENDOTHELIUM, VASCULAR; FEMALE; HUMANS; MICE; MICE, NUDE; MIDDLE CEREBRAL ARTERY; NEOPLASM TRANSPLANTATION; NEOPLASMS, EXPERIMENTAL; NEOVASCULARIZATION, PATHOLOGIC; NEOVASCULARIZATION, PHYSIOLOGIC; PEPTIDE FRAGMENTS; TRANSPLANTATION, HETEROLOGOUS; TREATMENT OUTCOME;

EID: 3042704848     PISSN: 09696970     EISSN: None     Source Type: Journal    
DOI: 10.1023/B:AGEN.0000037335.17717.bf     Document Type: Article

References (44)

1. Naidu A, Quon D, Cordell B. Beta-amyloid peptide produced in vitro is degraded by proteinases released by cultured cells. J Biol Chem 1995; 270: 1369-74.
2. Ellis RJ, Olichney JM, Thai LJ et al. Cerebral amyloid angiopathy in the brains of patients with Alzheimer's disease: The CERAD experience, Part XV. Neurology 1996; 46: 1592-6.
3. Kalaria RN. The blood-brain barrier and cerebrovascular pathology in Alzheimer's disease. Ann N Y Acad Sci 1999; 893: 113-25.
4. Fezoui Y, Hartley DM, Harper JD et al. An improved method of preparing the amyloid beta-protein for fibrillogenesis and neurotoxicity experiments. Amyloid 2000; 7: 166-78.
5. Halverson K, Fraser PE, Kirschner DA, Lansbury Jr PT. Molecular determinants of amyloid deposition in Alzheimer's disease: Conformational studies of synthetic beta-protein fragments. Biochemistry 1990; 29: 2639-44.
6. Dings RP, Arroyo MM, Lockwood NA et al. Beta-sheet is the bioactive Conformation of the anti-angiogenic anginex peptide. Biochem J 2003; 373: 281-8.
7. Dings RP, van der Schaft DW, Hargittai B et al. Anti-tumor activity of the novel angiogenesis inhibitor anginex. Cancer Lett 2003; 194: 55-66.
8. Hohenester E, Sasaki T, Oslen BR, Timpl R. Crystal structure of the angiogenesis inhibitor endostatin at 1.5 A resolution. EMBO J 1998; 17: 1656-64.
9. Kranenburg O, Kroon-Batenburg LM, Reijerkerk A et al. Recombinant endostatin forms amyloid fibrils that bind and are cytotoxic to murine neuroblastoma cells in vitro. FEBS Lett 2003; 539: 149-55.
10. Mayo KH, Roongta V, Barker S et al. NMR solution structure of the 32-kDa platelet factor 4 ELR-motif N-terminal chimera: A symmetric tetramer. Biochemistry 1995; 34: 11399-409.
11. Baeyens KJ, De Bondt HL, Raeymaekers A et al. The structure of mouse tumour-necrosis factor at 1.4 A resolution: Towards modulation of its selectivity and trimerization. Acta Crystallogr D Biol Crystallogr 1999; 55: 772-8.
12. Beamer LJ, Carroll SF, Eisenberg D. Crystal structure of human BPI and two bound phospholipids at 2.4 angstrom resolution. Science 1997; 276: 1861-4.
13. Passaniti A, Taylor RM, Pili R et al. A simple, quantitative method for assessing angiogenesis and antiangiogenic agents using reconstituted basement membrane, heparin, and fibroblast growth factor. Lab Invest 1992; 4: 519-28.
14. LeVine 3rd H. Quantification of beta-sheet amyloid fibril structures with thioflavin T. Meth Enzymol 1999; 309: 274-84.
15. Soto C, Sigurdsson EM, Morelli L et al. Beta-sheet breaker peptides inhibit fibrillogenesis in a rat brain model of amyloidosis: Implications for Alzheimer's therapy. Nat Med 1998; 7: 822-6.
16. Nicosia RF, Lin YJ, Hazelton D, Qian X. Endogenous regulation of angiogenesis in the rat aorta model. Role of vascular endothelial growth factor. Am J Pathol 1997; 151: 1379-85.
17. Kruger EA, Duray PH, Tsokos MG et al. Endostatin inhibits microvessel formation in the ex vivo rat aortic ring angiogenesis assay. Biochem Biophys Res Commun 2000; 268: 183-91.
18. Kuo YM, Crawford F, Mullan M et al. Elevated Abeta and apolipoprotein E in A betaPP transgenic mice and its relationship to amyloid accumulation in Alzheimer's disease. Mol Med 2000; 5: 430-9.
19. Takano S, Gately S, Jiang JB, Brem S. A diaminoantraquinone inhibitor of angiogenesis. J Pharm Exp Therap 1994; 271: 1027-33.
20. Takano S, Gately S, Neville ME et al. Suramin, an anticancer and angiosuppressive agent, inhibits endothelial cell binding of basic fibroblast growth factor, migration, proliferation, and induction of urokinase-type plasminogen activator. Cancer Res 1994; 54: 2654-60.
21. Gyorffy S, Palmer K, Gauldie J. Adenoviral vector expressing murine angiostatin inhibits a model of breast cancer metastatic growth in the lungs of mice. Am J Pathol 2001; 3: 1137-47.
22. Clarice K, Lee FT, Brechbiel MW et al. In vivo biodistribution of a humanized anti-Lewis Y monoclonal antibody (hu3S193) in MCF-7 xenografted BALB/c nude mice. Clin Cancer Res 2000; 6: 3621-8.
23. Miravalle L, Tokuda T, Chiarle R et al. Substitutions at codon 22 of Alzheimer's abeta peptide induce diverse conformational changes and apoptotic effects in human cerebral endothelial cells. J Biol Chem 2000; 35: 27110-6.
24. Eisenhauer PB, Johnson RJ, Wells JM et al. Toxicity of various amyloid beta peptide species in cultured human blood-brain barrier endothelial cells: Increased toxicity of dutch-type mutant. J Neurosci Res 2000; 6: 804-10.
25. Nicosia RF, Bonanno E, Villaschi S. Large-vessel endothelium switches to a microvascular phenotype during angiogenesis in collagen gel culture of rat aorta. Atherosclerosis 1992; 95: 191-9.
26. Jones MK, Wang H, Peskar BM et al. Inhibition of angiogenesis by nonsteroidal anti-inflammatory drugs: Insight into mechanisms and implications for cancer growth and ulcer healing. Nat Med 1999; 5: 1418-23.
27. Mancardi GL, Perdelli F, Rivano C et al. Thickening of the basement membrane of cortical capillaries in Alzheimer's disease. Acta Neuropathol 1980; 49: 79-83.
28. Kalaria RN, Hedera P. Differential degeneration of the cerebral microvasculature in Alzheimer's disease. NeuroReport 1995; 6: 477-80.
29. Kalaria RN, Pax AB. Increased collagen content of cerebral microvessels in Alzheimer's disease. Brain Res 1995; 705: 349-52.
30. Claudio L. Ultrastructural features of the blood-brain barrier in biopsy tissue from Alzheimer's disease patients. Acta Neupathol 1996; 91: 6-14.
31. Kalaria RN, Cohen DL, Premkumar DR et al. Vascular endothelial growth factor in Alzheimer's disease and experimental cerebral ischemia. Brain Res Mol Brain Res 1998; 62: 101-5.
32. Buee L. Hof PR, Delacourte A. Brain microvascular changes in Alzheimer's disease and other dementias. Ann N Y Acad Sci 1997; 826: 7-24.
33. Buee L, Hof PR, Bouras C et al. Pathological alterations of the cerebral microvasculature in Alzheimer's disease and related dementing disorders. Acta Neuropathol (Berl) 1994; 87: 469-80.
34. Fischer VW, Siddiqi A, Yusufaly Y. Altered angioarchitecture in selected areas of brains with Alzheimer's disease. Acta Neuropathol (Berl) 1990; 79: 672-9.
35. Suter O, Sunthorn T, Kraftsik R et al. Cerebral hypoperfusion generates cortical watershed microinfarcts in Alzheimer disease. Stroke 2002; 33: 1986-92.
36. Martinez-Hernandez A, Amenta PS. The basement membrane in pathology. Lab Invest 1983; 48: 656-77.
37. Takenouchi T, Munekata E. Trophic effects of substance P and beta-amyloid peptide on dibutyryl cyclic AMP-differentiated human leukemic (HL-60) cells. Life Sci 1995; 56: PL479-84.
38. Atwood CS, Obrenovich ME, Liu T et al. Amyloid-beta: A chameleon walking in two worlds: A review of the trophic and toxic properties of amyloid-beta. Brain Res Brain Res Rev 2003; 43: 1-16.
39. Paris D, Townsend KP, Obregon DF et al. Pro-inflammatory effect of freshly solubilized beta-amyloid peptides in the brain. Prostaglandins Other Lipid Mediat 2002; 70: 1-12.
40. Paris D, Townsend KP, Humphrey J et al. Statins inhibit A beta-neurotoxicity in vitro and A beta-induced vasoconstriction and inflammation in rat aortae. Atherosclerosis 2002; 161: 293-9.
41. Paris D, Town T, Mori T et al. Soluble beta-amyloid peptides mediate vasoactivity via activation of a pro-inflammatory pathway. Neurobiol Aging 2000; 21: 183-97.
42. Crawford F, Soto C, Suo Z et al. Alzheimer's beta-amyloid vasoactivity: Identification of a novel beta-amyloid conformational intermediate. FEBS Lett 1998; 436: 445-8.
43. Bush AI. The metallobiology of Alzheimer's disease. Trends Neurosci 2003; 26: 207-14.
44. Pan Q, Kleer CG, van Golen KL et al. Copper deficiency induced by tetrathiomolybdate suppresses tumor growth and angiogenesis. Cancer Res 2002; 62: 4854-9.